echinocandin B

a cyclic hexapeptide echinocandin antibiotic isolated from Aspergillus nidulans var. echinulatus with specific anti-yeast activity; inhibits beta-1,3-glucan synthesis

Networked: 11 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Hu, Xiao-Long: 1 article (11/2020)
2.	Hu, Zhong-Ce: 1 article (11/2020)
3.	Liu, Zhi-Qiang: 1 article (11/2020)
4.	Niu, Kun: 1 article (11/2020)
5.	Wu, Xu-Ping: 1 article (11/2020)
6.	Zheng, Yu-Guo: 1 article (11/2020)
7.	Zou, Shu-Ping: 1 article (11/2020)
8.	Ishwar, B: 1 article (11/2019)
9.	Manohar, S: 1 article (11/2019)
10.	Raghu, P: 1 article (11/2019)

Related Diseases

1.	Infections 02/01/1999 - "The lack of agents for infections caused by pathogenic fungi has demanded further investigation of a key lead structure which has shown promise, echinocandin B. " 12/01/1999 - "The pentyloxyterphenyl side chain derivative of echinocandin B, anidulafungin, is a 1,3-alpha-glucan synthesis inhibitor undergoing phase II clinical trials by Versicor and Eli Lilly, in various formulations, for the potential treatment of fungal and protozoal infections. " 09/01/1994 - "carinii developed severe infections within 5 weeks after inoculation and responded to treatments with an echinocandin B analog, LY302146, or trimethoprim plus sulfamethoxazole so that they had decreased numbers of P. "
2.	Mycoses (Diseases, Fungus) 11/01/2019 - "Anidulafungin, a new class of antifungal agent used for the treatment of chronic fungal infections, is derived from Echinocandin B nucleus, an intermediate metabolite of Echinocandin B produced by Aspergillus nidulans. " 10/01/2003 - "Anidulafungin, a 1,3-beta-glucan synthesis inhibitor and the pentyloxyterphenyl side chain derivative of echinocandin B, is being developed by Vicuron Pharmaceuticals Inc, under license from Eli Lilly & Co, for the potential treatment of fungal infection." 01/01/2003 - "Vicuron Pharmaceuticals (formerly Versicor Inc.) is developing anidulafungin [LY 303366, ECB, V-echinocandin, VEC, VER-02, VER 002], a lipopeptide echinocandin B derivative, for IV treatment of mycoses. " 04/01/1999 - "LY303366 is a semisynthetic analog of the antifungal lipopeptide echinocandin B that inhibits (1,3)-beta-D-glucan synthase and exhibits efficacy in animal models of human fungal infections. "
3.	Invasive Candidiasis 11/01/2020 - "Echinocandin B (ECB) is a key precursor of antifungal agent Anidulafungin, which has demonstrated clinical efficacy in patients with invasive candidiasis. "
4.	Pulmonary Aspergillosis 11/01/1998 - "Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits."
5.	Candidiasis (Moniliasis) 09/01/1999 - "Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits."

Related Drugs and Biologics

1.	Anidulafungin
2.	Lipopeptides
3.	Echinocandins
4.	Antifungal Agents
5.	Trimethoprim (Proloprim)
6.	Sulfamethoxazole
7.	Micafungin (FK463)
8.	Caspofungin (Cancidas)
9.	FR 901379
10.	pneumocandin B(0)